All Juan Carlos Jaramillo articles
-
NewsValneva vaccinates first participant in pediatric trial of single-shot Chikungunya vaccine
Valneva SE has announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and immunogenicity in children of two different dose levels of Valneva’s single-shot chikungunya vaccine.
-
NewsVaccine for Lyme disease one step closer with promising six-month results
A vaccine for Lyme disease is one step closer after Pfizer Inc and Valneva SE reported positive results in their antibody persistence data six months after completing a three-dose or two-dose schdule in children and adults with vaccine candidate VLA15.
